Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease
- Resource Type
- Article
- Source
- In
Clinical Gastroenterology and Hepatology February 2022 20(2):314-324 - Subject
CME - Language
- ISSN
- 1542-3565